Objective MACIVIVA is a highly interdisciplinary consortium among well established and innovative SMEs with scientific excellence and complementary industrial world-leading experts with unique expertise and know-how in virosome technology, spray and freeze drying, large scale manufacturing and packaging. MACIVIVA will pave the path to other large scale thermostable nanopharmaceuticals products for therapeutic and prophylactic vaccines and other potential applications for direct application by non-invasive routes.Liquid products are inherently prone to physical and/or chemical modifications and degradations. Solid vaccine dosage formats (e.g. powder) may prevent molecular motion and shear-induced degradation, and slow down degradation involving water and oxygen radicals, resulting in improved stability and enhanced shelf-life of vaccines. The cold chain storage is still fundamental for preserving the bioactivity of most liquid and freeze-dried vaccines, and a reconstitution step prior to administration is required for freeze dried vaccines that are usually administered intramuscularly or subcutaneously. These reconstituted freeze dried vaccines harbor important instability and must be used within hours and kept refrigerated. Because most liquid and reconstituted freeze-dried vaccines are susceptible to degradations, it may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection. For addressing liquid virosome-based vaccine instability and improving their shelf-life outside the cold chain, MACIVIVA will explore new galenic vaccine formulations through careful screening of excipients, stabilization and drying methods for generating new vaccine solid forms that can be easily self-administered. Robust “universal” manufacturing processes for upscale production of virosome dried powder for the non-invasive intranasal, oral and sublingual routes should be achieved by month 42. Fields of science engineering and technologymechanical engineeringmanufacturing engineeringmedical and health sciencesbasic medicineimmunologyimmunisationnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines Programme(s) H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme H2020-EU.2.1.2.1. - Developing next generation nanomaterials, nanodevices and nanosystems Topic(s) NMP-08-2014 - Scale-up of nanopharmaceuticals production Call for proposal H2020-NMP-2014-2015 See other projects for this call Sub call H2020-NMP-PILOTS-2014 Funding Scheme RIA - Research and Innovation action Coordinator MYMETICS BV Net EU contribution € 1 755 073,75 Address J h oortweg 21 2333 CH Leiden Netherlands See on map Region West-Nederland Zuid-Holland Agglomeratie Leiden en Bollenstreek Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 Participants (5) Sort alphabetically Sort by Net EU contribution Expand all Collapse all MYMETICS SA Switzerland Net EU contribution € 0,00 Address Route de la corniche 4 1066 Epalinges See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Schweiz/Suisse/Svizzera Région lémanique Vaud Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 792 493,75 BACHEM AG Switzerland Net EU contribution € 0,00 Address Hauptstrasse 144 4416 Bubendorf See on map Region Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Landschaft Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 1 307 525,00 UPPERTON LIMITED United Kingdom Net EU contribution € 1 647 777,50 Address Biocity nottingham pennyfoot street NG1 1GF Nottingham See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region East Midlands (England) Derbyshire and Nottinghamshire Nottingham Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CATALENT U.K. SWINDON ZYDIS LIMITED United Kingdom Net EU contribution € 1 061 723,13 Address Frankland road blagrove SN5 8YG Swindon See on map Region South West (England) Gloucestershire, Wiltshire and Bristol/Bath area Swindon Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00 CHIMERA BIOTEC GMBH Germany Net EU contribution € 874 312,50 Address Emil-figge-strasse 76a 44227 Dortmund See on map SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes Region Nordrhein-Westfalen Arnsberg Dortmund, Kreisfreie Stadt Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Website Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 0,00
